Grace TherapeuticsGRCE -2.71%31 Market Cap is $37.84 Mil as of Jun. 25, 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, Grace Therapeutics ranks worse than 67.71% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Grace Therapeutics's share price for the quarter that ended in Mar. 2026 was $4.63. Grace Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 16.02 Mil. Therefore, Grace Therapeutics's market cap for the quarter that ended in Mar. 2026 was $74.19 Mil.
Grace Therapeutics's quarterly market cap
increased
from Sep. 2025 ($42.06 Mil) to Dec. 2025 ($53.54 Mil) and
increased
from Dec. 2025 ($53.54 Mil) to Mar. 2026 ($74.19 Mil).
Grace Therapeutics's annual market cap
declined
from Mar. 2024 ($32.19 Mil) to Mar. 2025 ($31.28 Mil) but then
increased
from Mar. 2025 ($31.28 Mil) to Mar. 2026 ($74.19 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Grace Therapeutics's Enterprise Value for Today is $20.86 Mil.
Grace Therapeutics (NAS:GRCE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Grace Therapeutics Market Cap Related Terms
Grace Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Grace Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Grace Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Grace Therapeutics's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grace Therapeutics (GRCE) has a Market Cap of $37.84 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Grace Therapeutics and its competitors. According to the industry distribution chart, Grace Therapeutics ranks #969 out of 1431 companies in the Biotechnology industry, placing it in the top 67.7%.
Is Grace Therapeutics' Market Cap too high?
Grace Therapeutics' current Market Cap is $37.84 Mil. The Biotechnology industry median Market Cap is 117.63. Grace Therapeutics' value of $37.84 Mil is 67.8% below this industry median. Based on the distribution chart, Grace Therapeutics ranks #969 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Market Cap compare to PSTV and ATNM?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #969 out of 1431 companies for Market Cap. This places Grace Therapeutics in the lower half of its industry. The industry median Market Cap is 117.63. Grace Therapeutics' value of $37.84 Mil is 67.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grace Therapeutics's current Market Cap of $37.84 Mil is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Grace Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current Market Cap is $37.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Market Cap of $37.84 Mil. The current Market Cap is $37.84 Mil and 67.8% below the Biotechnology industry median of 117.63. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Market Cap is $37.84 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score
Get the complete analysis for GRCE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 
